Christopher Hite was appointed Director of Vera Therapeutics, Inc. As of November 14, 2026, Vera Therapeutics, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from March 9, 2026 to July 9, 2026, naming 2 appointments (Form 8-K, March 9, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Vera Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Vera Therapeutics, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-03-09 to 2026-07-09. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Vera Therapeutics, Inc. files it.
Also on the record for Vera Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 10, 2026 | Stake report, Schedule 13G, by STATE STREET CORPORATION | 4.6% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Kynam Capital Management, LP | 4.01% of the class | 5%+ stakes | Source |
| August 7, 2026 | Stake report, Schedule 13G, by STATE STREET CORPORATION | 5.8% of the class | 5%+ stakes | Source |
| July 30, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 7.4% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by T. Rowe Price Associates, Inc. | 6.4% of the class | 5%+ stakes | Source |
| April 1, 2026 | Stake report, Schedule 13G, by Point72 Asset Management, L.P. | 1.7% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| March 11, 2026 | Stake report, Schedule 13G, by Deep Track Capital, LP | 5.5% of the class | 5%+ stakes | Source |
| March 5, 2026 | Stake report, Schedule 13D/A, by Sofinnova Venture Partners X, L.P. ("SVP X") | 4% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by T. Rowe Price Associates, Inc. | 7.7% of the class | 5%+ stakes | Source |
| February 5, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 4.1% of the class | 5%+ stakes | Source |
| January 30, 2026 | Stake report, Schedule 13G, by The Vanguard Group | 5.03% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Vera Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Vera Therapeutics, Inc. and the records around it.
Vera Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Who owns it
Companies that share a holder
- Sofinnova Venture Partners X, L.P. ("SVP X") also filed stake reports on 1 other company: Jade Biosciences, Inc. (Mar 2026)
- Kynam Capital Management, LP also filed stake reports on 8 other companies: Celldex Therapeutics, Inc. (Aug 2026), CytomX Therapeutics, Inc. (Aug 2026), Viridian Therapeutics, Inc. (Aug 2026)
- Deep Track Capital, LP also filed stake reports on 60 other companies: Mentari Therapeutics, Inc. (Nov 2026), Alector, Inc. (Oct 2026), TCGX Acquisition Corp. II (Oct 2026)
Watch Vera Therapeutics, Inc.
Get an email when Vera Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Vera Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Vera Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Vera Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 14 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-07-09 | Reported | not named in the filing | 8-K, 2026-07-09 | ||
| 2026-03-09 | In | Director | 8-K, 2026-03-09 | ||
| 2026-03-09 | In | 8-K, 2026-03-09 |
Who leads Vera Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Christopher Hite, appointed (filed 2026-03-09).
New leaders reset buying decisions — get the Full Report on Vera Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Vera Therapeutics, Inc., with the record behind each one.
Find candidates like Director at Vera Therapeutics, Inc.Every change, in the filing's words
Reported
Nancy Bowman, M.D., Ph.D., will succeed Mr. Turner as the Company's Chief Regulatory Officer, effective as of August 3, 2026.
- On July 9, 2026, Vera Therapeutics, Inc. (the "Company") announced that William Turner will no longer serve as the Company's Chief Regulatory Officer and will transition to the role of Special Advisor for Regulatory Affairs, effective as of August 3, 2026.
Appointed: Christopher Hite, Director
On March 5, 2026, the board of directors (the "Board") of Vera Therapeutics, Inc. (the "Company") appointed Christopher Hite to the Board, effective immediately.
Appointed: Christopher Hite
Mr. Hite will serve as a Class III Director, with an initial term expiring at the Company's 2027 Annual Meeting of Stockholders.
- Contingent upon and effective as of Mr. Hite's appointment to the Board, Mr. Hite was automatically granted a nonstatutory stock option award (the "Option Grant") to purchase 24,937 shares of the Company's Class A common stock ("Common Stock") with a per-share exercise price of $38.85, pursuant to the Company's Amended and Restated Non-Employee Director Compensation Policy (as it may be amended from time to time, the "Policy").
- The Option Grant will vest monthly over a three-year period, subject to Mr. Hite's continuous service as of each such vesting date, and is otherwise subject to the same terms set forth in the Policy for initial grants to new directors.
- In addition, in accordance with the Policy, Mr. Hite will also receive an annual cash retainer of $45,000 for his service on the Board which will be pro-rated for 2026.
- Pursuant to the Policy, commencing with the Company's 2027 Annual Meeting of Stockholders, Mr. Hite will be eligible to receive an annual option grant to purchase the lesser of (i) 18,000 shares of Common Stock and (ii) the maximum number of shares of Common Stock that would result in the option having a grant date fair value of not more than $400,000, subject to his continuous service as of such date.
Tools for this story
Each opens in a new tab, filled in for Vera Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
